1. Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis
- Author
-
Oren Rom, Yuhao Liu, Alexandra C. Finney, Alia Ghrayeb, Ying Zhao, Yousef Shukha, Lu Wang, Krishani K. Rajanayake, Sandeep Das, Nabil A. Rashdan, Natan Weissman, Luisa Delgadillo, Bo Wen, Minerva T. Garcia-Barrio, Michael Aviram, Christopher G. Kevil, Arif Yurdagul, Christopher B. Pattillo, Jifeng Zhang, Duxin Sun, Tony Hayek, Eyal Gottlieb, Inbal Mor, and Y Eugene Chen
- Subjects
Mice, Knockout ,Glutamate-Cysteine Ligase ,Organic Chemistry ,Clinical Biochemistry ,Glycine ,Atherosclerosis ,Glutathione ,Biochemistry ,Plaque, Atherosclerotic ,Mice, Inbred C57BL ,Disease Models, Animal ,Mice ,Apolipoproteins E ,Superoxides ,Animals ,Humans - Abstract
Lower circulating levels of glycine are consistently reported in association with cardiovascular disease (CVD), but the causative role and therapeutic potential of glycine in atherosclerosis, the underlying cause of most CVDs, remain to be established. Here, following the identification of reduced circulating glycine in patients with significant coronary artery disease (sCAD), we investigated a causative role of glycine in atherosclerosis by modulating glycine availability in atheroprone mice. We further evaluated the atheroprotective potential of DT-109, a recently identified glycine-based compound with dual lipid/glucose-lowering properties. Glycine deficiency enhanced, while glycine supplementation attenuated, atherosclerosis development in apolipoprotein E-deficient (Apoe
- Published
- 2022